

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

The Pronucleotide Approach. I. Synthesis, Anti-HIV Activity and Preliminary Stability Studies of Mononucleoside *S,S*-Bis(O-acyl-2-oxyethyl) Phosphorodithiolates

N. Schlienger^a; C. Périgaud^a; G. Gosselin^a; I. Lefebvre^a; A. Pompon^a; A. -M. Aubertin^a; A. Kirn^b; J. -L. Imbach^a

^a Laboratoire de Chimie Bioorganique, UMR CNRS-USTL 5625, Université Montpellier II, Montpellier, France ^b Université Louis Pasteur, Institut de Virologie, Strasbourg, France

To cite this Article Schlienger, N. , Périgaud, C. , Gosselin, G. , Lefebvre, I. , Pompon, A. , Aubertin, A. -M. , Kirn, A. and Imbach, J. -L.(1997) 'The Pronucleotide Approach. I. Synthesis, Anti-HIV Activity and Preliminary Stability Studies of Mononucleoside *S,S*-Bis(O-acyl-2-oxyethyl) Phosphorodithiolates', *Nucleosides, Nucleotides and Nucleic Acids*, 16: 7, 1321 – 1324

To link to this Article: DOI: 10.1080/07328319708006180

URL: <http://dx.doi.org/10.1080/07328319708006180>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**THE PRONUCLEOTIDE APPROACH. I.
SYNTHESIS, ANTI-HIV ACTIVITY AND PRELIMINARY STABILITY
STUDIES OF MONONUCLEOSIDE *S,S'*-BIS(*O*-ACYL-2-OXYETHYL)
PHOSPHORODITHIOLATES**

N. Schlienger¹, C. Périgaud^{1*}, G. Gosselin¹, I. Lefebvre¹, A. Pompon¹, A.-M. Aubertin²,
A. Kirn² and J.-L. Imbach¹

¹Laboratoire de Chimie Bioorganique, UMR CNRS-USTL 5625, Université Montpellier II, Case courrier 008, Place E. Bataillon, 34095 Montpellier Cedex 5, France; ²Université Louis Pasteur, Institut de Virologie, INSERM U 74, 67000 Strasbourg, France

ABSTRACT: The synthesis, *in vitro* anti-HIV activity, and preliminary stability studies of several mononucleoside phosphorodithiolate derivatives incorporating a new kind of bio-labile phosphate-protection, namely *O*-pivaloyl-2-oxyethyl, are reported. Our preliminary results strongly support the hypothesis that such pronucleotides exert their biological effects *via* intracellular delivery of the corresponding 5'-mononucleotide.

We have recently demonstrated that mononucleoside phosphotriesters incorporating *S*-acyl-2-thioethyl *carboxyesterase-labile transient phosphate protections* (SATE pronucleotides, FIG. 1), allow the intracellular delivery of the corresponding 5'-mononucleotides.¹ Among the SATE groups, the *S*-pivaloyl-2-thioethyl group (tBuSATE) emerged as the most promising bio-labile protection for *in vivo* experiments on the basis of its pharmacokinetic properties.

We decided to extend our investigations in the design of new kinds of bio-labile phosphate protections by the synthesis and study of an isomeric form of SATE pronucleotides, namely mononucleoside *S,S'*-bis(*O*-acyl-2-oxyethyl) phosphorodithiolates (isoSATE pronucleotides, FIG. 1). Here, we report the synthesis, antiviral evaluation and preliminary pharmacokinetic data of phosphorodithiolate derivatives of 2',3'-dideoxyadenosine (ddA) and 2',3'-dideoxy-2',3'-dideoxythymidine (d4T), **1** and **2** respectively, which incorporate the *O*-pivaloyl-2-oxyethyl [tBu(iso)SATE, FIG. 1] bio-




Figure 1: Structure of the studied pronucleotides

labile phosphate protecting group. The studies were performed in comparison to the tBu(SATE) pronucleotide of ddA **3** (FIG. 1).

SYNTHESIS

The mononucleoside phosphorodithiolates **1** and **2** were obtained following an one-pot procedure adapted from a published oligonucleotide-phosphorodithioates synthesis,² involving (pyrrolidino)phosphoramidites and 1*H*-tetrazole activation (Scheme 1).


ANTI-HIV-1 ACTIVITY

The isoSATE pronucleotides **1** and **2** were evaluated for their inhibitory effects on the replication of HIV-1 in CEM-SS and in thymidine-kinase deficient cell lines (CEM/TK⁻) (TABLE 1). For comparison, the parent nucleosides ddA and d4T (and in the case of ddA, the bis(tBuSATE) pronucleotide **3**) were evaluated in the same experiments.

In the two cell culture systems, the anti-HIV-1 activities of the tBu(iso)SATE pronucleotide **1** were similar to those of their corresponding tBu(SATE) pronucleotide **3**, both types of isomeric pronucleotides being more potent inhibitors than ddA. Furthermore, the d4T derivative **2** showed high inhibitory effects in thymidine-deficient CEM cells while, as expected, d4T was weakly active in this cell line.

PRELIMINARY STABILITY STUDIES

The decomposition pathways and kinetic data of the isoSATE pronucleotide **1** were performed in culture medium and in total cell extracts. The proposed decomposition pathway (Scheme 2) may involve: (a) esterase-mediated activation leading to (**A**); (b) nucleophilic attack of the resulting free hydroxyl function on the phosphorus atom, giving the five-covalent intermediate (**B**); (c) conversion of (**B**) into the 2-mercaptoethyl




Scheme 1: Synthesis of the *t*Bu(iso)SATE promucleotides **1** and **2**

Table 1: Anti-HIV-1 activity of the pronucleotides **1-3** compared to their parent nucleosides ddA and d4T

	CEM-SS		CEM/TK ⁻	
	EC ₅₀ (M) ^a	CC ₅₀ (M) ^b	EC ₅₀ (M) ^a	CC ₅₀ (M) ^b
1	1.2 10 ⁻¹⁰	> 10 ⁻⁵	7.7 10 ⁻⁹	10 ⁻⁵
3	1 10 ⁻¹⁰	7.9 10 ⁻⁶	1.3 10 ⁻⁹	1.4 10 ⁻⁶
ddA	4.9 10 ⁻⁷	> 10 ⁻⁴	4.3 10 ⁻⁷	> 10 ⁻⁴
2	4.4 10 ⁻⁹	> 10 ⁻⁵	5.9 10 ⁻⁹	8 10 ⁻⁶
d4T	4 10 ⁻⁸	> 10 ⁻⁴	1.5 10 ⁻⁵	9.2 10 ⁻⁵

^a EC₅₀: 50% effective concentration or concentration required to inhibit the replication of HIV by 50%; ^b CC₅₀: 50% cytotoxic concentration or concentration required to reduce the viability of uninfected cells by 50%



Scheme 2: Proposed decomposition pathway of an isoSATE pronucleotide

phosphotriester (**C**); (d) spontaneous elimination of episulfide, affording the corresponding phosphorothiolate diester (**D**); (e) hydrolysis of (**D**) into the corresponding 5'-monophosphate by a similar mechanism (a-b-c-d) or by action of phosphodiesterases.

CONCLUSION

The present results demonstrate that isoSATE pronucleotides allow the efficient intracellular delivery of their parent nucleoside 5'-monophosphates. Further studies of isoSATE pronucleotides, particularly on the definite mechanisms involved in their decomposition, are in progress in our laboratory.

ACKNOWLEDGMENTS

This work was supported by grants from the Agence Nationale de Recherches sur le SIDA (ANRS). Grateful acknowledgment is made to ANRS for a fellowship (N.S.).

REFERENCES

1. Lefebvre, I.; Périgaud, C.; Pompon, A.; Aubertin, A.-M.; Girardet, J.-L.; Kirn, A.; Gosselin, G.; Imbach, J.-L. *J. Med. Chem.*, **1995**, *38*, 3941.
2. Wiesler, W. T.; Marshall, W. S.; Caruthers, M. H. in *Methods in Molecular Biology: Protocols for Nucleotides and Analogs*; Agrawal, S., Ed.; Humana Press Inc.: Totowa, 1993; Vol. 20, 191.